Hepatic pathology among patients without known liver disease undergoing bariatric surgery

Observations and a perspective from the Longitudinal Assessment of Bariatric Surgery (LABS) study

David E. Kleiner, Paul D. Berk, Jesse Y. Hsu, Anita P. Courcoulas, David Flum, Saurabh Khandelwal, John Pender, Alfons Pomp, James Roerig, Laura L. Machado, Bruce Wolfe, Steven H. Belle

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Liver biopsy is not routine during bariatric surgery. Alanine aminotransferase (ALT) is widely used to screen for liver disease. We assessed the relationship between ALT and pathology in biopsies from Longitudinal Assessment of Bariatric Surgery (LABS) patients with normal preoperative ALTs. Biopsies from the LABS-1 and LABS-2 studies were scored using the NASH CRN and Ishak systems. Diagnosis and histology were examined in relation to alanine aminotransferase (ALT) values. Six-hundred ninety-three suitable biopsies were evaluated. Biopsied patients had a median age of 45 years; 78.6% were female and 35.1% diabetic; median body mass index was 46 kg/m2. Six-hundred thirty-five biopsied patients had preoperative ALTs. Median ALT was 25 IU/L (interquartile range [IQR] 19-36 IU/L); 26.6% had an ALT>35 IU/L and 29.9% exceeded the more restrictive Prati criteria for normal. Using the Prati criteria, 7.9% of participants with normal ALT had steatohepatitis and 5.3% had≥stage 2 fibrosis. Logistic regression models were used to predict the probabilities of having bridging fibrosis/cirrhosis or a diagnosis of borderline/definite steatohepatitis in the unbiopsied LABS-2 sample. The proportion of biopsied participants with these findings was very similar to the modeled results from the unbiopsied cohorts. We estimated that 86.0% of participants with advanced fibrosis and 88.1% of participants with borderline/definite steatohepatitis were not biopsied and went undiagnosed. As ALT did not reliably exclude significant obesity-related liver disease in bariatric surgery patients, consideration should be given to routine liver biopsy during bariatric surgery and medical follow-up of significant hepatic pathology.

Original languageEnglish (US)
Pages (from-to)98-107
Number of pages10
JournalSeminars in Liver Disease
Volume34
Issue number1
DOIs
StatePublished - 2014

Fingerprint

Bariatric Surgery
Alanine Transaminase
Liver Diseases
Pathology
Liver
Biopsy
Fibrosis
Fatty Liver
Logistic Models
Histology
Body Mass Index
Obesity

Keywords

  • bariatric surgery
  • cirrhosis
  • liver biopsy
  • NAFLD
  • steatohepatitis

ASJC Scopus subject areas

  • Hepatology
  • Medicine(all)

Cite this

Hepatic pathology among patients without known liver disease undergoing bariatric surgery : Observations and a perspective from the Longitudinal Assessment of Bariatric Surgery (LABS) study. / Kleiner, David E.; Berk, Paul D.; Hsu, Jesse Y.; Courcoulas, Anita P.; Flum, David; Khandelwal, Saurabh; Pender, John; Pomp, Alfons; Roerig, James; Machado, Laura L.; Wolfe, Bruce; Belle, Steven H.

In: Seminars in Liver Disease, Vol. 34, No. 1, 2014, p. 98-107.

Research output: Contribution to journalArticle

Kleiner, David E. ; Berk, Paul D. ; Hsu, Jesse Y. ; Courcoulas, Anita P. ; Flum, David ; Khandelwal, Saurabh ; Pender, John ; Pomp, Alfons ; Roerig, James ; Machado, Laura L. ; Wolfe, Bruce ; Belle, Steven H. / Hepatic pathology among patients without known liver disease undergoing bariatric surgery : Observations and a perspective from the Longitudinal Assessment of Bariatric Surgery (LABS) study. In: Seminars in Liver Disease. 2014 ; Vol. 34, No. 1. pp. 98-107.
@article{26bbc744e2374e22bd9911e817d0bd1b,
title = "Hepatic pathology among patients without known liver disease undergoing bariatric surgery: Observations and a perspective from the Longitudinal Assessment of Bariatric Surgery (LABS) study",
abstract = "Liver biopsy is not routine during bariatric surgery. Alanine aminotransferase (ALT) is widely used to screen for liver disease. We assessed the relationship between ALT and pathology in biopsies from Longitudinal Assessment of Bariatric Surgery (LABS) patients with normal preoperative ALTs. Biopsies from the LABS-1 and LABS-2 studies were scored using the NASH CRN and Ishak systems. Diagnosis and histology were examined in relation to alanine aminotransferase (ALT) values. Six-hundred ninety-three suitable biopsies were evaluated. Biopsied patients had a median age of 45 years; 78.6{\%} were female and 35.1{\%} diabetic; median body mass index was 46 kg/m2. Six-hundred thirty-five biopsied patients had preoperative ALTs. Median ALT was 25 IU/L (interquartile range [IQR] 19-36 IU/L); 26.6{\%} had an ALT>35 IU/L and 29.9{\%} exceeded the more restrictive Prati criteria for normal. Using the Prati criteria, 7.9{\%} of participants with normal ALT had steatohepatitis and 5.3{\%} had≥stage 2 fibrosis. Logistic regression models were used to predict the probabilities of having bridging fibrosis/cirrhosis or a diagnosis of borderline/definite steatohepatitis in the unbiopsied LABS-2 sample. The proportion of biopsied participants with these findings was very similar to the modeled results from the unbiopsied cohorts. We estimated that 86.0{\%} of participants with advanced fibrosis and 88.1{\%} of participants with borderline/definite steatohepatitis were not biopsied and went undiagnosed. As ALT did not reliably exclude significant obesity-related liver disease in bariatric surgery patients, consideration should be given to routine liver biopsy during bariatric surgery and medical follow-up of significant hepatic pathology.",
keywords = "bariatric surgery, cirrhosis, liver biopsy, NAFLD, steatohepatitis",
author = "Kleiner, {David E.} and Berk, {Paul D.} and Hsu, {Jesse Y.} and Courcoulas, {Anita P.} and David Flum and Saurabh Khandelwal and John Pender and Alfons Pomp and James Roerig and Machado, {Laura L.} and Bruce Wolfe and Belle, {Steven H.}",
year = "2014",
doi = "10.1055/s-0034-1371083",
language = "English (US)",
volume = "34",
pages = "98--107",
journal = "Seminars in Liver Disease",
issn = "0272-8087",
publisher = "Thieme Medical Publishers",
number = "1",

}

TY - JOUR

T1 - Hepatic pathology among patients without known liver disease undergoing bariatric surgery

T2 - Observations and a perspective from the Longitudinal Assessment of Bariatric Surgery (LABS) study

AU - Kleiner, David E.

AU - Berk, Paul D.

AU - Hsu, Jesse Y.

AU - Courcoulas, Anita P.

AU - Flum, David

AU - Khandelwal, Saurabh

AU - Pender, John

AU - Pomp, Alfons

AU - Roerig, James

AU - Machado, Laura L.

AU - Wolfe, Bruce

AU - Belle, Steven H.

PY - 2014

Y1 - 2014

N2 - Liver biopsy is not routine during bariatric surgery. Alanine aminotransferase (ALT) is widely used to screen for liver disease. We assessed the relationship between ALT and pathology in biopsies from Longitudinal Assessment of Bariatric Surgery (LABS) patients with normal preoperative ALTs. Biopsies from the LABS-1 and LABS-2 studies were scored using the NASH CRN and Ishak systems. Diagnosis and histology were examined in relation to alanine aminotransferase (ALT) values. Six-hundred ninety-three suitable biopsies were evaluated. Biopsied patients had a median age of 45 years; 78.6% were female and 35.1% diabetic; median body mass index was 46 kg/m2. Six-hundred thirty-five biopsied patients had preoperative ALTs. Median ALT was 25 IU/L (interquartile range [IQR] 19-36 IU/L); 26.6% had an ALT>35 IU/L and 29.9% exceeded the more restrictive Prati criteria for normal. Using the Prati criteria, 7.9% of participants with normal ALT had steatohepatitis and 5.3% had≥stage 2 fibrosis. Logistic regression models were used to predict the probabilities of having bridging fibrosis/cirrhosis or a diagnosis of borderline/definite steatohepatitis in the unbiopsied LABS-2 sample. The proportion of biopsied participants with these findings was very similar to the modeled results from the unbiopsied cohorts. We estimated that 86.0% of participants with advanced fibrosis and 88.1% of participants with borderline/definite steatohepatitis were not biopsied and went undiagnosed. As ALT did not reliably exclude significant obesity-related liver disease in bariatric surgery patients, consideration should be given to routine liver biopsy during bariatric surgery and medical follow-up of significant hepatic pathology.

AB - Liver biopsy is not routine during bariatric surgery. Alanine aminotransferase (ALT) is widely used to screen for liver disease. We assessed the relationship between ALT and pathology in biopsies from Longitudinal Assessment of Bariatric Surgery (LABS) patients with normal preoperative ALTs. Biopsies from the LABS-1 and LABS-2 studies were scored using the NASH CRN and Ishak systems. Diagnosis and histology were examined in relation to alanine aminotransferase (ALT) values. Six-hundred ninety-three suitable biopsies were evaluated. Biopsied patients had a median age of 45 years; 78.6% were female and 35.1% diabetic; median body mass index was 46 kg/m2. Six-hundred thirty-five biopsied patients had preoperative ALTs. Median ALT was 25 IU/L (interquartile range [IQR] 19-36 IU/L); 26.6% had an ALT>35 IU/L and 29.9% exceeded the more restrictive Prati criteria for normal. Using the Prati criteria, 7.9% of participants with normal ALT had steatohepatitis and 5.3% had≥stage 2 fibrosis. Logistic regression models were used to predict the probabilities of having bridging fibrosis/cirrhosis or a diagnosis of borderline/definite steatohepatitis in the unbiopsied LABS-2 sample. The proportion of biopsied participants with these findings was very similar to the modeled results from the unbiopsied cohorts. We estimated that 86.0% of participants with advanced fibrosis and 88.1% of participants with borderline/definite steatohepatitis were not biopsied and went undiagnosed. As ALT did not reliably exclude significant obesity-related liver disease in bariatric surgery patients, consideration should be given to routine liver biopsy during bariatric surgery and medical follow-up of significant hepatic pathology.

KW - bariatric surgery

KW - cirrhosis

KW - liver biopsy

KW - NAFLD

KW - steatohepatitis

UR - http://www.scopus.com/inward/record.url?scp=84899652361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899652361&partnerID=8YFLogxK

U2 - 10.1055/s-0034-1371083

DO - 10.1055/s-0034-1371083

M3 - Article

VL - 34

SP - 98

EP - 107

JO - Seminars in Liver Disease

JF - Seminars in Liver Disease

SN - 0272-8087

IS - 1

ER -